Averill, the new biopharmaceutical fund managed by a team under the Suvretta Capital umbrella, posted blowout returns for its first partial year of trading, according to a communication sent to clients and seen by Institutional Investor.
Averill, which manages about $350 million and began trading on March 23, gains between 195 percent and 221 percent in 2020, depending on the share class, according to the communication.
